4.21

6.70% -0.30

Relay Therapeutics Inc (RLAY)

Overview News Price History Option Chain Financials Why RLAY Down? Discussions Forecast

Relay Therapeutics Inc stock is traded at $4.21, with a volume of 495.36K. It is down -6.70% in the last 24 hours and down -8.92% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Previous Close:

$4.51

Open:

$4.53

24h Volume:

495.36K

Relative Volume:

0.22

Market Cap:

$754.90M

Revenue:

$25.55M

Net Income/Loss:

$-341.97M

P/E Ratio:

-1.5036

EPS:

-2.8

Net Cash Flow:

$-304.44M

1W Performance:

-5.87%

1M Performance:

-8.92%

6M Performance:

-36.44%

1Y Performance:

-51.86%

1-Day Range:

$4.195

$4.589

1-Week Range:

$4.195

$4.86

52-Week Range:

$3.50

$11.16

Relay Therapeutics Inc Stock (RLAY) Company Profile

Name

Relay Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

617-370-8837

Address

399 BINNEY STREET, CAMBRIDGE

Employee

294

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RLAY's Discussions on Twitter

Compare RLAY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLAY Relay Therapeutics Inc	4.205	754.90M	25.55M	-341.97M	-304.44M	-2.80
VRTX Vertex Pharmaceuticals Inc	474.04	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.89	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.69	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.71	28.75B	3.30B	-501.07M	1.03B	-2.1146

Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-10-24	Resumed	Goldman	Buy
Sep-10-24	Upgrade	Jefferies	Hold → Buy
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight
Apr-20-23	Upgrade	Jefferies	Underperform → Hold
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy
Apr-13-23	Initiated	Raymond James	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Sep-30-22	Initiated	Barclays	Equal Weight
Sep-02-22	Initiated	Stifel	Buy
Jun-06-22	Initiated	Jefferies	Underperform
Feb-01-22	Initiated	Berenberg	Buy
Jul-21-21	Initiated	BofA Securities	Buy
Dec-15-20	Reiterated	H.C. Wainwright	Buy
Dec-08-20	Initiated	JMP Securities	Mkt Outperform
Nov-05-20	Initiated	H.C. Wainwright	Buy
Aug-10-20	Initiated	Cowen	Outperform
Aug-10-20	Initiated	Goldman	Buy
Aug-10-20	Initiated	Guggenheim	Buy
Aug-10-20	Initiated	JP Morgan	Neutral

View All

Relay Therapeutics Inc Stock (RLAY) Latest News

09:24 AM

RLAY’s Market Whiplash: 9.47% YTD Rise, -1.31% Plunge in 30 Days - The InvestChronicle

09:24 AM

07:05 AM

Analysts Set Expectations for RLAY Q1 Earnings - Armenian Reporter

07:05 AM

Feb 06, 2025

Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News

Feb 06, 2025

Feb 05, 2025

BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com

Feb 05, 2025

Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily

Feb 05, 2025

SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News

Feb 05, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Feb 05, 2025

Feb 04, 2025

How should investors view Relay Therapeutics Inc (RLAY)? - US Post News

Feb 04, 2025

Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat

Feb 04, 2025

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat

Feb 04, 2025

Feb 03, 2025

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat

Feb 03, 2025

Jan 31, 2025

Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com

Jan 31, 2025

Jan 30, 2025